Altogether, these data suggest that heterozygous RUNX2 mutations in both CCD patients impair osteogenic maturation by reducing the expression of RUNX2-downstream genes, such as SPARC, as well as by reducing p53 levels (Figure 8). The gene discussed is SPARC; the disease is cleidocranial dysplasia 1.